ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ETRA / options
SRZN (37) VALN (46) RGNX (27) ENTX (41) ⌘ Pro Terminal →

Electra Therapeutics Inc. (ETRA) Options Positioning, Max Pain & Unusual Sweeps

$7.31 -9.75% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $7.17

Electra Therapeutics Inc. (ETRA) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $508.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ETRA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ETRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Electra Therapeutics Inc. (NASDAQ: ETRA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $7.31 (-9.75% 1D, market cap $508.4M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 9/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ETRA compare to SRZN and VALN in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ETRA carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SRZN (Surrozen Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $516.9M) and VALN (Valneva SE) posts a D grade (46/100 RQD, P/E N/A, ROIC —, cap $517.1M). Among the 5-stock peer group, ETRA leads on earnings multiple (N/A) while ENTX leads on capital efficiency (-33.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ETRA?
▼

For Electra Therapeutics Inc. (ETRA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #404 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $7.17 (-1.94%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.4% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D-
025507510043
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Cash (12)Whales (3)SEC (13)Macro (6)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-6.7% Base Target
$16 Bull$7 Base$5 Bear
📬 FREE ETRA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ETRA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (43/100 Composite)
🔍 WHY ETRA SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (28% of score)

SEC XBRL Trailing 12 Months: 0.4% FCF Margin ($14.2M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
51
Grade C-$9.32-7.6% Next Q
Q2 (-2Q)
48
Grade D$8.61-2.8% Next Q
Q3 (-1Q)
46
Grade D$8.37-12.7% Next Q
Current
43
Grade D-$7.31-6.7% Hist 90D α
Trajectory: C- (51) → D- (43)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ETRA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ETRA currently carries a cautious 43/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.92) and Max Pain ($7.68) forces dealer call-delta covering toward $16.28.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ETRA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ETRA Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 43%NO 57%Trade / Inspect Odds →
CALL VS. PUT WHALE SHARE
— (No Active Options Snapshot)
Put/Call Ratio: — (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
— (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
±12.5%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (ETRA)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for ETRA.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ETRA)

  • ✓Walkthrough of ETRA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ETRA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -44.83%▼ SUPPORT BREAKDOWN
2026-11-02O $8.14H $8.38L $7.06C $7.31VOL 385.5K
SUP: $8.06SMA50: $9.92SMA200: $9.92
$16.09$13.64$11.20$8.75$6.30SUP $8.06$7.312026-09-182026-09-292026-10-092026-10-212026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ETRA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ETRA Butterfly Map → + Track ETRA →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ETRA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ETRA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ETRA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ETRA)

Health Care Rank #404 of 1016 ⚔️ SRZN vs ETRA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ETRA vs. SRZN, VALN, RGNX, ENTX)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Electra Therapeutics Inc. (ETRA) ranks #404 by composite RQD confidence (43/100, grade D-) and #439 by equity capitalization ($508.4M). Within this direct 5-issuer industry benchmark cohort, ETRA leads on earnings valuation at N/A trailing P/E, while ENTX leads on capital efficiency and profitability with -33.6% ROIC and 0.0% gross margin. VALN currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with ETRA at 43/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ETRA ACTIVE
Electra Therapeutics Inc.
D- 43/100 — — — -9.75% $508.4M Benchmark Subject
SRZN
Surrozen Inc.
D- 37/100 — — -35.0% -0.07% $516.9M /srzn-vs-etra →
VALN
Valneva SE
D 46/100 — — — -2.38% $517.1M /valn-vs-etra →
RGNX
REGENXBIO Inc.
E 27/100 — — -35.0% -0.56% $475.3M /rgnx-vs-etra →
ENTX
Entera Bio Ltd.
D- 41/100 — 0.0% -33.6% -3.44% $556.6M /entx-vs-etra →

2. ETRA Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Electra Therapeutics Inc. (ETRA) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $508.4M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. ETRA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ETRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Electra Therapeutics Inc. (NASDAQ: ETRA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $7.31 (-9.75% 1D, market cap $508.4M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 9/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.

How does ETRA compare to SRZN and VALN in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ETRA carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SRZN (Surrozen Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $516.9M) and VALN (Valneva SE) posts a D grade (46/100 RQD, P/E N/A, ROIC —, cap $517.1M). Among the 5-stock peer group, ETRA leads on earnings multiple (N/A) while ENTX leads on capital efficiency (-33.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ETRA?

For Electra Therapeutics Inc. (ETRA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #404 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ETRA trading relative to its 50-day, 200-day, and 52-week technical levels?

ETRA last traded at $7.31 (-9.75% on volume of 385,470 shares), positioning the stock -26.31% below its 50-day simple moving average ($9.92) and -19.93% below its 200-day simple moving average ($9.13). Across its 52-week range of $7.06 to $15.50, ETRA sits at the 3.0% percentile with a 14-day RSI of 24.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($6.40 to $8.22).

Direct Sub-Reports: ETRA RQD Cockpit ETRA 12M Forecast ETRA Earnings & Move ETRA Dividends & DRIP ETRA Insiders & 13F ETRA Whale Options ETRA Profit Sankey ETRA News & Why
ROARABLE RATING BRIEF • RQD 43/100 (D-) ✓ SEC XBRL & RQD VERIFIED

ETRA — Electra Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Electra Therapeutics Inc. (ETRA) earns a live Roarable RQD composite score of 43/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $7.31 (-9.75% 1D, market capitalization $508.4M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (13/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (9/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Electra Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry,. The profile does not describe its products, customers, or revenue model. — The market capitalization is listed at $0.5B in the profile.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 43/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $7.06 – $15.50 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The investor should watch the sensitivity of ETRA to net liquidity conditions, since the signal assigns a high beta to that factor, and note that a 6.00x elasticity implies amplified exposure to changes in that backdrop. Second-order bottlenecks cannot be identified from the supplied data.

  • Key Question #1: Can ETRA sustain or expand its — operating margin and — ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $15.50 52-week high?
  • Key Question #3: How sensitive is ETRA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ETRA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Electra Therapeutics Inc. (ETRA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ETRA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ETRA Bull vs. Bear Conversation Board — What's Your Call at $7.31?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ETRA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ETRA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $8.70 (+19.0%)
📌 Pinned Debate

The forensic balance sheet pillar scores 13 of 20 with Altman Z of 2.5 and Debt/Equity of 0.5, the strongest pillar in the rating.

Don't sleep on ETRA's setup in Health Care. The forensic balance sheet pillar scores 13 of 20 with Altman Z of 2.5 and Debt/Equity of 0.5, the strongest pillar in the rating.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (43/100) backs up the fundamental quality.

SectorRotator 🐂 BULL

@SkepticalCFA Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Biological Products (No Diagnostic Substances). If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $5.99 (-18.1%)
Spot @ $7.31

The Butterfly liquidity signal is flagged BEARISH at severity 94 with a 6.00x Net Liquidity beta and a Macro Tailwind Score of 18/100.

Here is the bear case nobody on the bull side wants to address on ETRA: The Butterfly liquidity signal is flagged BEARISH at severity 94 with a 6.00x Net Liquidity beta and a Macro Tailwind Score of 18/100.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Biological Products (No Diagnostic Substances) triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%